Direkt zum Inhalt
Merck
  • Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice.

Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice.

PloS one (2014-07-25)
Jonathan T Sockolosky, Saul Kivimäe, Francis C Szoka
ZUSAMMENFASSUNG

We explore a strategy to substantially increase the half-life of recombinant proteins by genetic fusion to FcIII, a 13-mer IgG-Fc domain binding peptide (IgGBP) originally identified by DeLano and co-workers at Genentech [DeLano WL, et al. (2000) Science 287:1279-1283]. IgGBP fusion increases the in vivo half-life of proteins by enabling the fusion protein to bind serum IgG, a concept originally introduced by DeLano and co-workers in a patent but that to the best of our knowledge has never been pursued in the scientific literature. To further investigate the in vitro and in vivo properties of IgGBP fusion proteins, we fused FcIII to the C-terminus of a model fluorescent protein, monomeric Katushka (mKate). mKate-IgGBP fusions are easily expressed in Escherichia coli and bind specifically to human IgG with an affinity of ∼ 40 nM and ∼ 20 nM at pH 7.4 and pH 6, respectively, but not to mouse or rat IgG isotypes. mKate-IgGBP binds the Fc-domain of hIgG1 at a site overlapping the human neonatal Fc receptor (hFcRn) and as a consequence inhibits the binding of hIgG1 to hFcRn in vitro. High affinity binding to human IgG also endows mKate-IgGBP with a long circulation half-life of ∼ 8 hr in mice, a 75-fold increase compared to unmodified mKate. Thus, IgGBP fusion significantly reduces protein clearance by piggybacking on serum IgG without substantially increasing protein molecular weight due to the small size of the IgGBP. These attractive features could result in protein therapies with reduced dose frequency and improved patient compliance.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ampicillin, anhydrous, 96.0-102.0% (anhydrous basis)
Sigma-Aldrich
Ethylendiamintetraessigsäure -Lösung, 0.02% in DPBS (0.5 mM), sterile-filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure, anhydrous, crystalline, BioReagent, suitable for cell culture
Sigma-Aldrich
Ethylendiamintetraessigsäure, 99.995% trace metals basis
Sigma-Aldrich
Isopropyl-β-D-thiogalactopyranosid -Lösung, ReadyMade IPTG solution for Blue-white screening
Sigma-Aldrich
Ethylendiamintetraessigsäure, ACS reagent, 99.4-100.6%, powder
SAFC
Isopropyl β-D-1-Thiogalactopyranosid
Sigma-Aldrich
IPTG, ≥99% (TLC), ≤0.1% Dioxane
USP
Ampicillin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Ethylendiamintetraessigsäure, anhydrous, BioUltra, ≥99% (titration)
Sigma-Aldrich
5-Carboxy-tetramethylrhodamin-N-succinimidylester, BioReagent, suitable for fluorescence
Sigma-Aldrich
Ethylendiamintetraessigsäure Dinatriumsalz -Lösung, BioUltra, for molecular biology, pH 8.0, ~0.5 M in H2O
Sigma-Aldrich
Isopropyl β-D-1-Thiogalactopyranosid, ≥99% (TLC)
Sigma-Aldrich
DL-Histidin, ≥99% (TLC)
Sigma-Aldrich
Ethylendiamintetraessigsäure, purified grade, ≥98.5%, powder
Sigma-Aldrich
Ampicillin, meets USP testing specifications
Sigma-Aldrich
Ethylendiamintetraessigsäure, ≥98.0% (KT)
Histidin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-D-Allose, rare aldohexose sugar
Supelco
Ampicillin, analytical standard
Sigma-Aldrich
Ethylendiamintetraessigsäure, BioUltra, ≥99.0% (KT)
Ampicillin, anhydrous, European Pharmacopoeia (EP) Reference Standard